# TCF3

## Overview
TCF3, or transcription factor 3, is a gene that encodes a basic helix-loop-helix (bHLH) transcription factor, which plays a pivotal role in the regulation of gene expression across various biological processes. The TCF3 protein is involved in DNA binding and dimerization, essential for its function in transcriptional regulation. It is known to form homodimers or heterodimers, influencing cellular processes such as differentiation, proliferation, and lineage commitment. TCF3 is particularly significant in the context of Wnt signaling, where it acts as a transcriptional repressor, modulating pathways critical for osteogenesis, neural development, and stem cell maintenance. The gene is also implicated in several hematological malignancies, with mutations and translocations affecting its normal function and contributing to disease pathogenesis (Snider2001Inhibition; Liu2013TCF3; Yamazaki2020Burkitt).

## Structure
TCF3, also known as transcription factor 3, is a basic helix-loop-helix (bHLH) protein that plays a crucial role in DNA binding and dimerization. The primary structure of TCF3 includes a conserved bHLH domain, which is essential for its function in gene regulation (Snider2001Inhibition). The secondary structure of TCF3 features alpha helices within the bHLH motif, facilitating its interaction with DNA (Snider2001Inhibition).

In terms of tertiary structure, TCF3 undergoes folding that enables effective DNA interaction, which is critical for its role in transcriptional regulation (Snider2001Inhibition). The quaternary structure of TCF3 allows it to form homodimers or heterodimers, which are important for its function in various cellular processes (Snider2001Inhibition).

TCF3 is subject to post-translational modifications, such as phosphorylation, which can influence its activity and interactions (Snider2001Inhibition). The gene also produces splice variant isoforms, including E12 and E47, which have distinct roles in regulating target genes and are implicated in conditions like Burkitt lymphoma (Yamazaki2020Burkitt). These isoforms contribute to the functional diversity of TCF3 in different biological contexts.

## Function
TCF3, also known as transcription factor 3, is a basic helix-loop-helix (bHLH) transcription factor that plays a significant role in various cellular processes, including differentiation, proliferation, and lineage commitment. In the context of osteogenesis, TCF3 acts as a positive regulator, modulating the effects of canonical Wnt signaling. It is crucial for osteogenic differentiation, as evidenced by its role in promoting bone formation in periodontal ligament stem cells (PDLSCs) both in vitro and in vivo (Liu2013TCF3).

In neural progenitor cells, TCF3 functions as a transcriptional repressor of Wnt signaling, maintaining the undifferentiated state of these cells during neocortical development. It suppresses neuronal differentiation by antagonizing the neurogenic function of Wnt signaling, thereby preserving the neural stem cell population (Kuwahara2014Tcf3).

In the skin, TCF3 regulates the differentiation of multipotent stem cells, particularly in the hair follicle. It acts as a transcriptional repressor, influencing the balance between stem cell maintenance and differentiation. TCF3 is prominently expressed in the bulge region of hair follicles, where it helps maintain the stem cell population by repressing epidermal terminal differentiation and promoting characteristics of the follicle outer root sheath (Merrill2001Tcf3).

## Clinical Significance
Mutations and alterations in the TCF3 gene are implicated in several hematological malignancies. In Hodgkin lymphoma (HL), a susceptibility variant located at chromosome 19p13.3 within intron 2 of the TCF3 gene has been identified. This variant is associated with a reduced risk of HL, with an odds ratio of 0.81, suggesting a protective effect (Cozen2014A).

In B-cell precursor acute lymphoblastic leukemia (BCP-ALL), the TCF3-PBX1 fusion gene, resulting from a t(1;19)(q23;p13) translocation, is a recurrent genetic alteration. This fusion acts as an oncogenic transcription factor, contributing to chemotherapy resistance and relapse (Eldfors2016Idelalisib). Another fusion, TCF3-HLF, associated with the t(17;19)(q22;p13) translocation, is linked to poor prognosis and early relapse in BCP-ALL (Lejman2020Comprehensive).

In Burkitt lymphoma (BL), mutations in the TCF3 gene affect alternative splicing, particularly in exon 18b, leading to dysregulation of target genes such as PTPN6 and CCND3. These mutations contribute to BL pathogenesis by altering TCF3's normal interactions and splicing regulation (Yamazaki2020Burkitt).

The TCF3-ZNF384 fusion is found in certain leukemias, including B-cell acute lymphoblastic leukemia (B-ALL) and mixed phenotype acute leukemia (MPAL), and is associated with poor steroid response and high relapse rates (Lin2021Leukemia).

## Interactions
TCF3, a transcription factor, engages in various interactions with proteins and nucleic acids, playing a significant role in gene regulation. TCF3 interacts with β-catenin, forming a complex that is crucial for regulating gene expression in processes such as limb development and neural tube closure. This interaction is part of the Wnt/β-catenin signaling pathway, where TCF3 acts as a transcriptional repressor, and its repression is counteracted by Wnt signaling (Wu2012Function).

TCF3 also interacts with I-mfa domain proteins, which inhibit its DNA binding and transcriptional activity. I-mfa binds to TCF3, preventing the formation of the β-catenin-TCF3 complex on DNA, thus inhibiting transcriptional activation in the Wnt pathway (Snider2001Inhibition). This interaction is significant in developmental processes such as dorsal axis formation in Xenopus embryos (Snider2001Inhibition).

In embryonic stem cells, TCF3 co-occupies genomic sites with pluripotency factors like Oct4, Sox2, and Nanog, forming part of the core regulatory circuitry. It acts as a repressor of pluripotency genes, and its interaction with these factors is crucial for maintaining the balance between pluripotency and differentiation (Cole2008Tcf3).


## References


[1. (Snider2001Inhibition) Lauren Snider, Hilary Thirlwell, Jeffrey R. Miller, Randall T. Moon, Mark Groudine, and Stephen J. Tapscott. Inhibition of tcf3 binding by i-mfa domain proteins. Molecular and Cellular Biology, 21(5):1866–1873, March 2001. URL: http://dx.doi.org/10.1128/mcb.21.5.1866-1873.2001, doi:10.1128/mcb.21.5.1866-1873.2001. This article has 45 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.21.5.1866-1873.2001)

[2. (Eldfors2016Idelalisib) S. Eldfors, H. Kuusanmäki, M. Kontro, M.M. Majumder, A. Parsons, H. Edgren, T. Pemovska, O. Kallioniemi, K. Wennerberg, N. Gökbuget, T. Burmeister, K. Porkka, and C. Heckman. Idelalisib sensitivity and mechanisms of disease progression in relapsed tcf3-pbx1 acute lymphoblastic leukemia. European Journal of Cancer, 61:S136, July 2016. URL: http://dx.doi.org/10.1016/s0959-8049(16)61481-8, doi:10.1016/s0959-8049(16)61481-8. This article has 0 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1016/s0959-8049(16)61481-8)

[3. (Lejman2020Comprehensive) Monika Lejman, Monika Włodarczyk, Joanna Zawitkowska, and Jerzy R. Kowalczyk. Comprehensive chromosomal aberrations in a case of a patient with tcf3-hlf-positive bcp-all. BMC Medical Genomics, April 2020. URL: http://dx.doi.org/10.1186/s12920-020-0709-y, doi:10.1186/s12920-020-0709-y. This article has 4 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s12920-020-0709-y)

[4. (Cozen2014A) W. Cozen, M. N. Timofeeva, D. Li, A. Diepstra, D. Hazelett, M. Delahaye-Sourdeix, C. K. Edlund, L. Franke, K. Rostgaard, D. J. Van Den Berg, V. K. Cortessis, K. E. Smedby, S. L. Glaser, H.-J. Westra, L. L. Robison, T. M. Mack, H. Ghesquieres, A. E. Hwang, A. Nieters, S. de Sanjose, T. Lightfoot, N. Becker, M. Maynadie, L. Foretova, E. Roman, Y. Benavente, K. A. Rand, B. N. Nathwani, B. Glimelius, A. Staines, P. Boffetta, B. K. Link, L. Kiemeney, S. M. Ansell, S. Bhatia, L. C. Strong, P. Galan, L. Vatten, T. M. Habermann, E. J. Duell, A. Lake, R. N. Veenstra, L. Visser, Y. Liu, K. Y. Urayama, D. Montgomery, V. Gaborieau, L. M. Weiss, G. Byrnes, M. Lathrop, P. Cocco, T. Best, A. D. Skol, H.-O. Adami, M. Melbye, J. R. Cerhan, A. Gallagher, G. M. Taylor, S. L. Slager, P. Brennan, G. A. Coetzee, D. V. Conti, K. Onel, R. F. Jarrett, H. Hjalgrim, A. van den Berg, and J. D. McKay. A meta-analysis of hodgkin lymphoma reveals 19p13.3 tcf3 as a novel susceptibility locus. Nature Communications, June 2014. URL: http://dx.doi.org/10.1038/ncomms4856, doi:10.1038/ncomms4856. This article has 75 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/ncomms4856)

[5. (Lin2021Leukemia) Na Lin, Xiaojing Yan, Dali Cai, and Lei Wang. Leukemia with tcf3-znf384 rearrangement as a distinct subtype of disease with distinct treatments: perspectives from a case report and literature review. Frontiers in Oncology, July 2021. URL: http://dx.doi.org/10.3389/fonc.2021.709036, doi:10.3389/fonc.2021.709036. This article has 3 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2021.709036)

[6. (Cole2008Tcf3) Megan F. Cole, Sarah E. Johnstone, Jamie J. Newman, Michael H. Kagey, and Richard A. Young. Tcf3 is an integral component of the core regulatory circuitry of embryonic stem cells. Genes &amp; Development, 22(6):746–755, March 2008. URL: http://dx.doi.org/10.1101/gad.1642408, doi:10.1101/gad.1642408. This article has 407 citations.](https://doi.org/10.1101/gad.1642408)

[7. (Wu2012Function) Chun-I Wu, Jackson A. Hoffman, Brian R. Shy, Erin M. Ford, Elaine Fuchs, Hoang Nguyen, and Bradley J. Merrill. Function of wnt/β-catenin in counteracting tcf3 repression through the tcf3–β-catenin interaction. Development, 139(12):2118–2129, June 2012. URL: http://dx.doi.org/10.1242/dev.076067, doi:10.1242/dev.076067. This article has 94 citations and is from a peer-reviewed journal.](https://doi.org/10.1242/dev.076067)

[8. (Merrill2001Tcf3) Bradley J. Merrill, Uri Gat, Ramanuj DasGupta, and Elaine Fuchs. Tcf3 and lef1 regulate lineage differentiation of multipotent stem cells in skin. Genes &amp; Development, 15(13):1688–1705, July 2001. URL: http://dx.doi.org/10.1101/gad.891401, doi:10.1101/gad.891401. This article has 468 citations.](https://doi.org/10.1101/gad.891401)

[9. (Yamazaki2020Burkitt) Takashi Yamazaki, Lizhi Liu, Erin G. Conlon, and James L. Manley. Burkitt lymphoma-related tcf3 mutations alter tcf3 alternative splicing by disrupting hnrnph1 binding. RNA Biology, 17(10):1383–1390, June 2020. URL: http://dx.doi.org/10.1080/15476286.2020.1772559, doi:10.1080/15476286.2020.1772559. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/15476286.2020.1772559)

[10. (Liu2013TCF3) W Liu, Y Liu, T Guo, C Hu, H Luo, L Zhang, S Shi, T Cai, Y Ding, and Y Jin. Tcf3, a novel positive regulator of osteogenesis, plays a crucial role in mir-17 modulating the diverse effect of canonical wnt signaling in different microenvironments. Cell Death &amp; Disease, 4(3):e539–e539, March 2013. URL: http://dx.doi.org/10.1038/cddis.2013.65, doi:10.1038/cddis.2013.65. This article has 44 citations.](https://doi.org/10.1038/cddis.2013.65)

[11. (Kuwahara2014Tcf3) Atsushi Kuwahara, Hiroshi Sakai, Yuanjiang Xu, Yasuhiro Itoh, Yusuke Hirabayashi, and Yukiko Gotoh. Tcf3 represses wnt–β-catenin signaling and maintains neural stem cell population during neocortical development. PLoS ONE, 9(5):e94408, May 2014. URL: http://dx.doi.org/10.1371/journal.pone.0094408, doi:10.1371/journal.pone.0094408. This article has 52 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0094408)